Cadonilimab plus chemotherapy ± bevacizumab as 1L treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): a randomized, double-blind, placebo-controlled phase 3 study (Compassion-16)

被引：0
|
作者：
Wu, Xiaohua [1 ]
Sun, Yang [2 ]
Yang, Hongying [3 ]
Wang, Jing [4 ,5 ]
Lou, Hanmei [6 ]
Li, Dan [7 ]
Wang, Ke [8 ]
Zhang, Hui [9 ]
Wu, Tao [10 ]
Li, Yuzhi [11 ]
Wang, Chunyan [12 ]
Li, Guiling [13 ]
Wang, Yifeng [14 ]
Li, Dapeng [15 ]
Tang, Ying [16 ]
Pan, Mei [17 ]
Cai, Hongyi [18 ]
Liu, Ting [19 ]
Xia, Michelle [19 ]
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fujian Med Univ, Clin Oncol Sch, Fujian Canc Hosp, Fuzhou, Peoples R China
[3] Yunnan Canc Hosp, Kunming, Peoples R China
[4] Cent South Univ, Hunan Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[5] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha, Peoples R China
[6] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[7] Southwest Med Univ, Affiliated Hosp, Luzhou, Peoples R China
[8] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[9] Hebei Med Univ, Hosp 4, Shijiazhuang, Peoples R China
[10] Changde First Peoples Hosp, Changde, Peoples R China
[11] Bengbu Med Univ, Affiliated Hosp 1, Bengbu, Peoples R China
[12] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[13] Tongji Med Coll, Union Hosp, Wuhan, Peoples R China
[14] Southern Med Univ, Zhujiang Hosp, Guangzhou, Peoples R China
[15] Shandong First Med Univ, Canc Hosp, Jinan, Peoples R China
[16] Chongqing Univ, Affiliated Canc Hosp, Chongqing, Peoples R China
[17] Jiangxi Maternal & Child Hlth Hosp, Nanchang, Peoples R China
[18] Gansu Prov Hosp, Lanzhou, Peoples R China
[19] Akeso Biopharm Inc, Zhongshan, Peoples R China
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2024年 / 34卷 / SUPPL_3期
关键词：
D O I：
10.1136/ijgc-2024-IGCS.2
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB014/#167
引用
收藏
页码：A1 / A2
页数：2
相关论文
共 50 条
  • [31] RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)
    Robert, N. J.
    Dieras, V.
    Glaspy, J.
    Brufsky, A.
    Bondarenko, I.
    Lipatov, O.
    Perez, E.
    Yardley, D.
    Zhou, X.
    Phan, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] AMAGINE-1: a phase 3, randomized, double-blind, placebo-controlled study of brodalumab in subjects with psoriasis
    Papp, K.
    Reich, K.
    Leonardi, C.
    Paul, C.
    Blauvelt, A.
    Baran, W.
    Bolduc, C.
    Toth, D.
    Langley, R. G.
    Cather, J.
    Gottlieb, A. B.
    Thaci, D.
    Milmont, C. E.
    Li, J.
    Klekotka, P.
    Kricorian, G.
    Nirula, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 171 (06) : E119 - E120
  • [33] Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer
    Bendell, Johanna C.
    Ervin, Thomas J.
    Gallinson, David
    Singh, Jaswinder
    Wallace, James A.
    Saleh, Mansoor N.
    Vallone, Marcy
    Phan, See-Chun
    Hack, Stephen P.
    CLINICAL COLORECTAL CANCER, 2013, 12 (03) : 218 - 222
  • [34] Cediranib combined with carboplatin and paclitaxel in patients with metastatic or recurrent cervical cancer (CIRCCa): a randomised, double-blind, placebo-controlled phase 2 trial
    Symonds, R. Paul
    Gourley, Charlie
    Davidson, Susan
    Carty, Karen
    McCartney, Elaine
    Rai, Debbie
    Banerjee, Susana
    Jackson, David
    Lord, Rosemary
    McCormack, Mary
    Hudson, Emma
    Reed, Nicholas
    Flubacher, Maxine
    Jankowska, Petra
    Powell, Melanie
    Dive, Caroline
    West, Catharine M. L.
    Paul, James
    LANCET ONCOLOGY, 2015, 16 (15): : 1515 - 1524
  • [35] Phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2-locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49
    Schmid, Peter
    Sohn, Joo Hyuk
    Jerez Gilarranz, Yolanda
    Gonzalez-Cortijo, Lucia
    Sonnenblick, Amir
    Sabanathan, Dhanusha
    Korbenfeld, Ernesto
    Egle, Daniel
    Poirier, Brigitte
    Zagouri, Flora
    Matikas, Alexios
    Aksoy, Sercan
    Demirci, Umut
    Ramos-Elias, Pier
    Im, Seock-Ah
    Cardoso, Fatima
    Jia, Liyi
    Hirshfield, Kim
    Tryfonidis, Konstantinos
    Rugo, Hope S.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 : 233 - 234
  • [36] Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer
    Sternberg, Cora
    Armstrong, Andrew
    Pili, Roberto
    Ng, Siobhan
    Huddart, Robert
    Agarwal, Neeraj
    Khvorostenko, Denis
    Lyulko, Olexiy
    Brize, Arija
    Vogelzang, Nicholas
    Delva, Remy
    Harza, Mihai
    Thanos, Anastasios
    James, Nicholas
    Werbrouck, Patrick
    Boegemann, Martin
    Hutson, Thomas
    Milecki, Piotr
    Chowdhury, Simon
    Gallardo, Enrique
    Schwartsmann, Gilberto
    Pouget, Jean-Christophe
    Baton, Frederique
    Nederman, Thore
    Tuvesson, Helen
    Carducci, Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (22) : 2636 - U136
  • [37] A randomised, double-blind, placebo-controlled phase II study of setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (rmSCCHN)
    Rullan, A.
    Adkins, D. R.
    Bossi, P.
    Cohen, E. E. W.
    Daste, A.
    Harrington, K. J.
    Le Tourneau, C.
    Licitra, L. F.
    Little, N.
    Morris, T.
    Ottensmeier, C. H. H.
    Reinwald, M.
    Rutkowski, T.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S863 - S864
  • [38] A double-blind, randomized, placebo-controlled, phase 2 study of maintenance enzastaurin with 5-fluorouracil/leucovorin plus bevacizumab after first-line therapy for metastatic colorectal cancer
    Wolff, Robert A.
    Fuchs, Martin
    Di Bartolomeo, Maria
    Hossain, Anwar M.
    Stoffregen, Clemens
    Nicol, Steven
    Heinemann, Volker
    CANCER, 2012, 118 (17) : 4132 - 4138
  • [39] A phase 3 randomized, placebo-controlled double-blind study of ARN-509 plus abiraterone acetate (AA) in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).
    Rathkopf, Dana E.
    Attard, Gerhardt
    Efstathiou, Eleni
    Yu, Margaret K.
    Griffin, Thomas W.
    Todd, Mary Beth
    Wu, Daphne
    Kheoh, Thian
    Zhao, Xin
    Saad, Fred
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [40] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Holgado, Esther
    Iwata, Hiroji
    Masuda, Norikazu
    Torregroza Otero, Marco
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhao, Jing
    Aktan, Gursel
    Karantza, Vassiliki
    Schmid, Peter
    LANCET, 2020, 396 (10265): : 1817 - 1828
12345